206 related articles for article (PubMed ID: 29064427)
1. The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes.
Lulli D; Carbone ML; Pastore S
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064427
[TBL] [Abstract][Full Text] [Related]
2. Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes.
Kanda N; Watanabe S
Endocrinology; 2007 May; 148(5):2317-25. PubMed ID: 17255201
[TBL] [Abstract][Full Text] [Related]
3. Topical Plant Polyphenols Prevent Type I Interferon Signaling in the Skin and Suppress Contact Hypersensitivity.
Carbone ML; Lulli D; Passarelli F; Pastore S
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200670
[TBL] [Abstract][Full Text] [Related]
4. BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.
Hoyer S; Eberlein V; Schuler G; Berking C; Heinzerling L; Schaft N; Dörrie J
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769379
[TBL] [Abstract][Full Text] [Related]
5. BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells.
Sanagawa A; Hotta Y; Mori N; Tomita N; Kataoka T; Tohkin M; Kimura K
Anticancer Drugs; 2021 Nov; 32(10):1076-1083. PubMed ID: 34232935
[TBL] [Abstract][Full Text] [Related]
6. IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes.
Kanda N; Shimizu T; Tada Y; Watanabe S
Eur J Immunol; 2007 Feb; 37(2):338-50. PubMed ID: 17274000
[TBL] [Abstract][Full Text] [Related]
7. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin.
Lulli D; Carbone ML; Pastore S
Oncotarget; 2016 Jul; 7(30):47777-47793. PubMed ID: 27322144
[TBL] [Abstract][Full Text] [Related]
9. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.
Unsworth AJ; Bye AP; Kriek N; Sage T; Osborne AA; Donaghy D; Gibbins JM
Platelets; 2019; 30(6):762-772. PubMed ID: 30252580
[TBL] [Abstract][Full Text] [Related]
10. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
11. Sustained Tumor Control With MAPK Inhibition in
Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
[TBL] [Abstract][Full Text] [Related]
12. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
Roskoski R
Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
[TBL] [Abstract][Full Text] [Related]
13. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
14. Essential involvement of cross-talk between IFN-gamma and TNF-alpha in CXCL10 production in human THP-1 monocytes.
Qi XF; Kim DH; Yoon YS; Jin D; Huang XZ; Li JH; Deung YK; Lee KJ
J Cell Physiol; 2009 Sep; 220(3):690-7. PubMed ID: 19472212
[TBL] [Abstract][Full Text] [Related]
15. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
[TBL] [Abstract][Full Text] [Related]
17. Suppression of thymus- and activation-regulated chemokine (TARC/CCL17) production by 3-O-β-D-glucopyanosylspinasterol via blocking NF-κB and STAT1 signaling pathways in TNF-α and IFN-γ-induced HaCaT keratinocytes.
Jung MR; Lee TH; Bang MH; Kim H; Son Y; Chung DK; Kim J
Biochem Biophys Res Commun; 2012 Oct; 427(2):236-41. PubMed ID: 22943853
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS
Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2.
Fujishita T; Kajino-Sakamoto R; Kojima Y; Taketo MM; Aoki M
Cancer Sci; 2015 Jun; 106(6):692-699. PubMed ID: 25855137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
